한미사이언스

008930KOSPI기타 금융업

57.6 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment20.6 / 25

Momentum3.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 18.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Science operates as a business holding company, generating revenue through equity income from subsidiaries, patent and trademark licensing fees, and healthcare and pharmaceutical wholesale businesses. The company focuses on innovation across medical devices, food, beauty care, and IT solutions, and expanded its portfolio through the 2022 acquisition of Hanmi Healthcare.

Number of Employees

489people

Average Salary

72.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.26Industry Average 9.681.5Point

1.8x industry avg (risky)

PBR

2.12Industry Average 0.460.0Point

4.6x industry avg (risky)

ROE

13.09Industry Average 5.417.0Point

2.4x industry avg (excellent)

Debt Ratio

4.83Industry Average 16.698.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲9.9% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.8% (declining, 3yr)

Detailed News Sentiment

21 totalPositive 20Neutral 0Negative 1Average Sentiment Score 82.6

Positive
한미약품 오너 우군 라데팡스, 이번엔 오스코텍 창업주 지원사격
한미사이언스 관련 오스코텍 창업주 지원으로 긍정적인 기업 이미지 강화.
Positive
김재교 한미사이언스 대표, 자사주 1000주 추가 취득
김재교 대표의 추가 자사주 매입으로 한미사이언스의 주주 가치 증대 기대.
Negative
[의약품 유통 미스터리]② ‘4% 거품’의 비밀…당신이 비싼 약값을 내...
의약품 유통 문제로 인해 고가의 약값 부담과 품절 사태가 발생하여 한미사이언스의 부정적 영향이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 29,700Won52-week high 51,90052-week low 29,700

1-month return0.0Point

1m -18.85% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Neutral최대주주등소유주식변동신고서2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral주식등의대량보유상황보고서(일반)2026-06-02
Neutral기업지배구조보고서공시2026-06-01
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (소네페글루타이드 (Sonefpeglutide; LAPS GLP2 agonist; HM15912) 기술이전 계약 체결)2026-06-01